Keywords: ph, iii, trovax, data, renal, cancer, expected

Ph III Trovax data in renal cancer expected 2009

Article | 25 February 2008

Print This

UK-based gene medicine firm Oxford BioMedica says that the independent Data Safety Monitoring Board for the Phase III TRIST study ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in